- Home
- LAB vs CDTX Comparison
LAB vs CDTX Comparison
Compare LAB & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- CDTX
- Stock Information
- Founded
- LAB 1999
- CDTX 2012
- Country
- LAB United States
- CDTX United States
- Employees
- LAB N/A
- CDTX N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAB Industrials
- CDTX Health Care
- Exchange
- LAB Nasdaq
- CDTX Nasdaq
- Market Cap
- LAB 372.1M
- CDTX 333.3M
- IPO Year
- LAB 2011
- CDTX 2015
- Fundamental
- Price
- LAB $1.05
- CDTX $21.02
- Analyst Decision
- LAB Buy
- CDTX Strong Buy
- Analyst Count
- LAB 2
- CDTX 9
- Target Price
- LAB $2.50
- CDTX $41.29
- AVG Volume (30 Days)
- LAB 1.3M
- CDTX 202.2K
- Earning Date
- LAB 07-30-2025
- CDTX 08-12-2025
- Dividend Yield
- LAB N/A
- CDTX N/A
- EPS Growth
- LAB N/A
- CDTX N/A
- EPS
- LAB N/A
- CDTX N/A
- Revenue
- LAB $169,687,000.00
- CDTX $302,000.00
- Revenue This Year
- LAB N/A
- CDTX N/A
- Revenue Next Year
- LAB $12.18
- CDTX N/A
- P/E Ratio
- LAB N/A
- CDTX N/A
- Revenue Growth
- LAB 33.86
- CDTX N/A
- 52 Week Low
- LAB $0.92
- CDTX $10.14
- 52 Week High
- LAB $2.41
- CDTX $28.42
- Technical
- Relative Strength Index (RSI)
- LAB 48.48
- CDTX 39.72
- Support Level
- LAB $1.02
- CDTX $21.14
- Resistance Level
- LAB $1.12
- CDTX $22.60
- Average True Range (ATR)
- LAB 0.07
- CDTX 1.54
- MACD
- LAB 0.00
- CDTX -0.51
- Stochastic Oscillator
- LAB 46.67
- CDTX 12.57
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.